096530.KQ
Strong BuyFull HouseAI neutralSeegene, Inc. · Healthcare · South Korea · $1.1B
KRW 36,900 -1.1% · close 2 Oct · scored 6 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Seegene is a global diagnostic solutions provider specializing in multiplex molecular diagnostics and PCR technologies. The firm retains a sound balance sheet and decent momentum, but post-pandemic normalization continues to weigh on valuation support without positive internal corporate signals.
ABOUT SEEGENE, INC.
Read
Seegene, Inc. is a leading South Korean molecular diagnostics company specializing in multiplex PCR technologies for infectious diseases and oncology. The company's proprietary platforms allow for highly accurate and simultaneous detection of multiple pathogens. Its innovation and rapid response to global health crises, such as COVID-19, have established it as a significant player in the diagnostics market.
FINANCIAL SUMMARY (KRW)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4T | 853.6B | 367.4B | 414.3B | 474.2B | -23.3% | 509.8B | 548.6B | 620.1B | 14.4% |
| EPS (KRW) | 10,359 | 3,586 | 14.00 | -190.00 | 1,047 | -43.6% | 1,048 | 1,941 | 1,987 | 37.8% |
| Shares | 52.2M | 49.8M | 46.0M | 46.1M | 45.6M | -12.8% | 45.6M | — | — | — |
| Debt | 159.1B | 159.2B | 141.8B | 143.6B | 129.9B | -4.9% | 130.4B | — | — | — |
| Equity | 1.1T | 1.1T | 1.0T | 990.2B | 1.0T | -1.6% | — | — | — | — |
| Op CF | 334.0B | 319.0B | 94.9B | 85.4B | 149.3B | -18.2% | 159.1B | — | — | — |
| Inv CF | -102.7B | -104.0B | -278.3B | 34.7B | -133.2B | — | — | — | — | — |
| Fin CF | -110.3B | -144.5B | -156.7B | -63.7B | -64.0B | — | — | — | — | — |
Swung more than 67% of stocks we rank over the past year (52% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 096530.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 096530.KQ | Seegene, Inc.(you) | $1.1B | 98 | Strong Buy |
| 145020.KQ | Hugel, Inc. | $1.5B | 86 | Strong Buy |
| 214450.KQ | PharmaResearch Co., Ltd. | $2.5B | 80 | Strong Buy |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $4.4B | 61 | Hold |
| 048870.KQ | Synergy Innovation Co., Ltd. | $96M | 64 | Hold |
| 251120.KQ | BIO-FD&C Co.,Ltd. | $58M | 73 | Buy |
| 234690.KQ | GC WellBeing Corporation | $119M | 54 | Hold |
| 086900.KQ | Medy-Tox Inc. | $321M | 34 | Sell |
| 005690.KS | Pharmicell Co., Ltd. | $556M | 21 | Sell |
| 340450.KQ | GC Genome Corporation | $143M | 45 | Hold |
Peer medians: ROE -0.3% · P/E 17.1x · Gross margin 43.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.